Aesculap Biologics, LLC Announces First Human Implantation of NOVOCART® 3D Autologous Chondrocyte Product
Aesculap Biologics, LLC, a division of Aesculap, Inc. focused on biological approaches to the repair and regeneration of diseased or damaged tissues, is pleased to announce that the first clinical study patient was implanted with the company’s NOVOCART® 3D product in August 2014. NOVOCART 3D, part of an FDA Investigational New Drug (IND) Phase 3 randomized, partially blinded multi-center study, is a matrix induced autologous chondrocyte product designed to repair articular cartilage defects of the knee. Kenneth R. Zaslav, M.D., a board-certified orthopedic surgeon with Advanced